Deborah Collyar: What's In It for Patients?

First International Summit on Interventional Pharmacoeconomics

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Matthew Seymour, MD: A Clinical Trialist’s Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Apr

Today In Oncology

Deborah Collyar: What's In It for Patients?

Related Videos

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Matthew Seymour, MD: A Clinical Trialist’s Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Machine Learning Program May Enhance Transplantation Risk Assessment in Patients With Myelofibrosis

Exploring Impact of COVID 19 Pandemic on Colorectal Cancer Screening Diagnosis

Patterns in Adherence to USPSTF Lung Cancer Screening Guidelines

AI Integration in Global Programs of CT Screening for Lung Cancer and Other Tobacco-Related Illnesses

Neoadjuvant Durvalumab Plus Chemotherapy for High-Risk Upper Tract Urothelial Carcinoma